Tag: GlobeNewswire

Materials Include a Technical Summary of the Photo-Mag Antenna Authored by Wolf Kohn, PhD, Chief Scientist of Project LightShift, and a Companion Explainer Video Prepared for Investor Audiences

Norwalk, CT, Nov. 02, 2026 (GLOBE NEWSWIRE) — Quantum Cyber N.V. (Nasdaq: QUCY) (“Quantum Cyber” or the “Company”), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced the publication of a package of investor explanatory materials on its corporate website, intended to help shareholders, analysts, and prospective investors understand the quantum antenna technology layer at the core of the Company’s platform.

The materials are available in the Investors section of the Company’s website at www.quantum-cyber.ai and consist of:

1. a technical summary presentation titled “Photo-Mag Antenna, Technical Summary,” authored by Wolf Kohn, PhD, Chief Scientist of Project LightShift, Inc., the inventor of the quantum photonic array technology exclusively licensed to Quantum Cyber for defense drone applications; and
2. a companion explainer video that walks investors through the same technology in plain language, prepared specifically for a non-technical investor audience.

On June 15, 2026, Quantum Cyber announced the execution of a definitive, exclusive worldwide Intellectual Property License Agreement with Project LightShift, Inc. covering the patent-protected quantum photonic array technology for integration into unmanned aerial vehicles and drone platforms used in defense and national security applications. Since that announcement, the Company has received a steady volume of investor questions seeking a clearer, more accessible description of what the quantum antenna technology actually is, how it works, and why management believes it differentiates the Company’s System-of-Systems platform from conventional autonomous defense integrators.

The materials published today respond to those questions. They are explanatory in nature, intended to make a highly technical body of work accessible to the investment community without diluting its substance.

The technical summary presentation, prepared by Dr. Kohn under Project LightShift, walks through the architecture and operating principles of the Photo-Mag Antenna, including:

• the polymer multilayer array architecture, built from a 25 by 25 grid of nano “DOTs” per unit, designed for high manufacturing yield and sub-0.1-watt power consumption;
• the signal conversion chain, in which the antenna subsystem traps photon streams at multiple frequencies, converts them into a single-frequency, phase-coherent photon stream, and routes the result into storage and processing;
• the DOT-level control circuit, which uses probability densities to incorporate quantum-level uncertainty into a practical, manufacturable control law;
• the DOT-level thermal control approach, driven by ambient light and molecular laser diodes;
• UV-lithography-based manufacturing controls, including the Hamiltonian ACS film generator and near-field self-assembly device under development to produce the array at scale.

Taken together, the summary describes the physical, control, and manufacturing layers that make the Photo-Mag Antenna a candidate for secure, frequency-agile sensing and communications in contested and denied environments, which is the capability the Company has licensed for defense drone and counter-UAS use.

The companion video runs approximately five minutes and presents the same material in a plain-language format intended for investors who want to understand the technology at a conceptual level without working through the technical slides. The video and the technical summary are designed to be used together, and investors who want a fuller picture are encouraged to review both.

About Quantum Cyber
Quantum Cyber N.V. (Nasdaq: QUCY) is a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications. The Company holds an exclusive worldwide license to Project LightShift’s patent-protected quantum photonic array technology for defense drone and unmanned aerial vehicle applications and is advancing vertically integrated U.S.-based manufacturing at its facility in Bridgeport, Connecticut. Additional information is available at www.quantum-cyber.ai.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements regarding the capabilities, development status, and intended applications of the Photo-Mag Antenna and the quantum photonic array technology licensed from Project LightShift, Inc., the Company’s System-of-Systems platform, the Company’s manufacturing plans, and the usefulness of the explanatory materials to investors. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties, many of which are outside the Company’s control, that could cause actual results to differ materially from those expressed or implied. Factors that could cause such differences include, without limitation, technical and engineering risk, manufacturing risk, regulatory risk, competition, defense budget and procurement risk, and the other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Investor Relations Contact
Arx Investor Relations
North American Equities Desk
qucy@arxhq.com

Materials Include a Technical Summary of the Photo-Mag Antenna Authored by Wolf Kohn, PhD, Chief Scientist of Project LightShift, and a Companion Explainer Video Prepared for Investor Audiences

Norwalk, CT, Nov. 02, 2026 (GLOBE NEWSWIRE) — Quantum Cyber N.V. (Nasdaq: QUCY) (“Quantum Cyber” or the “Company”), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced the publication of a package of investor explanatory materials on its corporate website, intended to help shareholders, analysts, and prospective investors understand the quantum antenna technology layer at the core of the Company’s platform.

The materials are available in the Investors section of the Company’s website at www.quantum-cyber.ai and consist of:

1. a technical summary presentation titled “Photo-Mag Antenna, Technical Summary,” authored by Wolf Kohn, PhD, Chief Scientist of Project LightShift, Inc., the inventor of the quantum photonic array technology exclusively licensed to Quantum Cyber for defense drone applications; and
2. a companion explainer video that walks investors through the same technology in plain language, prepared specifically for a non-technical investor audience.

On June 15, 2026, Quantum Cyber announced the execution of a definitive, exclusive worldwide Intellectual Property License Agreement with Project LightShift, Inc. covering the patent-protected quantum photonic array technology for integration into unmanned aerial vehicles and drone platforms used in defense and national security applications. Since that announcement, the Company has received a steady volume of investor questions seeking a clearer, more accessible description of what the quantum antenna technology actually is, how it works, and why management believes it differentiates the Company’s System-of-Systems platform from conventional autonomous defense integrators.

The materials published today respond to those questions. They are explanatory in nature, intended to make a highly technical body of work accessible to the investment community without diluting its substance.

The technical summary presentation, prepared by Dr. Kohn under Project LightShift, walks through the architecture and operating principles of the Photo-Mag Antenna, including:

• the polymer multilayer array architecture, built from a 25 by 25 grid of nano “DOTs” per unit, designed for high manufacturing yield and sub-0.1-watt power consumption;
• the signal conversion chain, in which the antenna subsystem traps photon streams at multiple frequencies, converts them into a single-frequency, phase-coherent photon stream, and routes the result into storage and processing;
• the DOT-level control circuit, which uses probability densities to incorporate quantum-level uncertainty into a practical, manufacturable control law;
• the DOT-level thermal control approach, driven by ambient light and molecular laser diodes;
• UV-lithography-based manufacturing controls, including the Hamiltonian ACS film generator and near-field self-assembly device under development to produce the array at scale.

Taken together, the summary describes the physical, control, and manufacturing layers that make the Photo-Mag Antenna a candidate for secure, frequency-agile sensing and communications in contested and denied environments, which is the capability the Company has licensed for defense drone and counter-UAS use.

The companion video runs approximately five minutes and presents the same material in a plain-language format intended for investors who want to understand the technology at a conceptual level without working through the technical slides. The video and the technical summary are designed to be used together, and investors who want a fuller picture are encouraged to review both.

About Quantum Cyber
Quantum Cyber N.V. (Nasdaq: QUCY) is a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications. The Company holds an exclusive worldwide license to Project LightShift’s patent-protected quantum photonic array technology for defense drone and unmanned aerial vehicle applications and is advancing vertically integrated U.S.-based manufacturing at its facility in Bridgeport, Connecticut. Additional information is available at www.quantum-cyber.ai.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements regarding the capabilities, development status, and intended applications of the Photo-Mag Antenna and the quantum photonic array technology licensed from Project LightShift, Inc., the Company’s System-of-Systems platform, the Company’s manufacturing plans, and the usefulness of the explanatory materials to investors. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties, many of which are outside the Company’s control, that could cause actual results to differ materially from those expressed or implied. Factors that could cause such differences include, without limitation, technical and engineering risk, manufacturing risk, regulatory risk, competition, defense budget and procurement risk, and the other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Investor Relations Contact
Arx Investor Relations
North American Equities Desk
qucy@arxhq.com

WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in November:

• Guggenheim 3rd Annual Healthcare Innovation Conference, fireside chat on Monday, November 9, 2026 at 8:30 a.m. ET in Boston.
• Stifel 2026 Healthcare Conference, fireside chat on Tuesday, November 10, 2026 at 1:20 p.m. ET in New York.
• Jefferies Global Healthcare Conference, fireside chat on Wednesday, November 18, 2026 at 3:00 p.m. GMT/10:00 a.m. ET in London.

A live webcast of each presentation will be available in the Investors section of the Company’s website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days.

About Crescent Biopharma

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.

Contacts

Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019

WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in November:

• Guggenheim 3rd Annual Healthcare Innovation Conference, fireside chat on Monday, November 9, 2026 at 8:30 a.m. ET in Boston.
• Stifel 2026 Healthcare Conference, fireside chat on Tuesday, November 10, 2026 at 1:20 p.m. ET in New York.
• Jefferies Global Healthcare Conference, fireside chat on Wednesday, November 18, 2026 at 3:00 p.m. GMT/10:00 a.m. ET in London.

A live webcast of each presentation will be available in the Investors section of the Company’s website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days.

About Crescent Biopharma

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.

Contacts

Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019

— Conference Call and Webcast 8:30 a.m. ET November 5 —

PURCHASE, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today announced that the Company will host a conference call and webcast on November 5, 2026, at 8:30 a.m. Eastern Time to report its financial results for the third quarter ended September 30, 2026, and provide a business update.

Conference Call & Webcast Details
Title:		Cognition Third Quarter 2026 Financial Results and Business Update
Date:		November 5, 2026
Time:		8:30 a.m. Eastern Time
Dial In:		Toll Free (US & Canada) 1-800-715-9871
US/International Toll:		1-646-307-1963
Conference ID:		9023814
Call me™:		https://registrations.events/easyconnect/9023814/recFvJxj663evg74H/
Webcast:		https://webcast.ir-events.com/bKXwO501v80

About Cognition Therapeutics 
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to helping millions of families seeking effective treatments for devastating neurodegenerative diseases through the development of novel, accessible therapies. The company has led pioneering research into the underlying mechanisms of degenerative nerve disorders. Our scientific approach builds on well-established biological pathways and translates across indications in which toxic oligomers drive disease progression, offering potential in dementia with Lewy bodies (DLB), Alzheimer’s disease, geographic atrophy, Parkinson’s, among others. The company’s lead candidate, zervimesine (CT1812), is an investigational once-daily oral therapy that has demonstrated promise in Phase 2 clinical trials in DLB and mild-to-moderate Alzheimer’s disease. Backed by nearly $200 million in National Institutes of Health and related foundation grants, Cognition Therapeutics continues to advance clinical research in its efforts to bring forth solutions that meet patients where they are and reduce caregiver burden. Learn more at cogrx.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including zervimesine (CT1812), and any expected or implied benefits or results, including that initial clinical results observed with respect to zervimesine will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of zervimesine, any analyses of the results therefrom, as well as statements regarding our regulatory plans, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. 

Contact Information:    Cognition Therapeutics, Inc.     info@cogrx.com

Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com

This press release was published by a CLEAR® Verified individual.

— Conference Call and Webcast 8:30 a.m. ET November 5 —

PURCHASE, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today announced that the Company will host a conference call and webcast on November 5, 2026, at 8:30 a.m. Eastern Time to report its financial results for the third quarter ended September 30, 2026, and provide a business update.

Conference Call & Webcast Details
Title:		Cognition Third Quarter 2026 Financial Results and Business Update
Date:		November 5, 2026
Time:		8:30 a.m. Eastern Time
Dial In:		Toll Free (US & Canada) 1-800-715-9871
US/International Toll:		1-646-307-1963
Conference ID:		9023814
Call me™:		https://registrations.events/easyconnect/9023814/recFvJxj663evg74H/
Webcast:		https://webcast.ir-events.com/bKXwO501v80

About Cognition Therapeutics 
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to helping millions of families seeking effective treatments for devastating neurodegenerative diseases through the development of novel, accessible therapies. The company has led pioneering research into the underlying mechanisms of degenerative nerve disorders. Our scientific approach builds on well-established biological pathways and translates across indications in which toxic oligomers drive disease progression, offering potential in dementia with Lewy bodies (DLB), Alzheimer’s disease, geographic atrophy, Parkinson’s, among others. The company’s lead candidate, zervimesine (CT1812), is an investigational once-daily oral therapy that has demonstrated promise in Phase 2 clinical trials in DLB and mild-to-moderate Alzheimer’s disease. Backed by nearly $200 million in National Institutes of Health and related foundation grants, Cognition Therapeutics continues to advance clinical research in its efforts to bring forth solutions that meet patients where they are and reduce caregiver burden. Learn more at cogrx.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including zervimesine (CT1812), and any expected or implied benefits or results, including that initial clinical results observed with respect to zervimesine will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of zervimesine, any analyses of the results therefrom, as well as statements regarding our regulatory plans, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. 

Contact Information:    Cognition Therapeutics, Inc.     info@cogrx.com

Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com

This press release was published by a CLEAR® Verified individual.

More of what Papa Johns does best, now in a bigger size for just $19.99

EDMONTON, Alberta, Nov. 02, 2026 (GLOBE NEWSWIRE) — Bigger is officially better at Papa Johns Canada. Beginning today, the brand is introducing its new 16-inch XL Pizza, bringing more of the flavour Canadians love in a size that lives up to its name.

At a full 16 inches, the new XL Pizza delivers big on flavour and quality. Made with fresh, never-frozen original dough, real cheese made from mozzarella, and signature pizza sauce made from vine-ripened tomatoes, it’s everything customers crave about Papa Johns, just bigger.

“There’s a reason we’re calling it XL. At 16 inches, it’s a seriously big pizza,” said Scott Lewis, General Manager, International Markets – Canada, at Papa Johns. “We wanted to give Canadians more of what they already love, and that’s exactly what we’ve done. It’s a great addition to our menu, and we’re excited to give customers another reason to order.”

For a limited time, Canadians can enjoy a 16-inch XL one-topping pizza for just $19.99 at participating Papa Johns restaurants nationwide. The offer is available from November 2, 2026, through January 3, 2027.

Customers can order through the Papa Johns app or online at papajohns.ca.

ABOUT PAPA JOHNS

Papa John’s International, Inc. (Nasdaq: PZZA) opened its doors in 1984 with one goal in mind: BETTER INGREDIENTS. BETTER PIZZA.^® Papa Johns believes that using high-quality ingredients leads to superior quality pizzas. Its original dough is made of only six ingredients and is fresh, never frozen. Papa Johns tops its pizzas with real cheese made from mozzarella, pizza sauce made with vine-ripened tomatoes that go from vine to can in the same day and meat free of fillers. It was the first national pizza delivery chain to announce the removal of artificial flavours and synthetic colours from its entire food menu. Papa Johns is co-headquartered in Atlanta, Ga. and Louisville, Ky. and is the world’s third-largest pizza delivery company with approximately 6,000 restaurants in approximately 50 countries and territories. For more information about the Company or to order pizza online, visit www.papajohns.ca or download the Papa Johns mobile app for iOS or Android.

Media – Papa Johns – North America

Michelle Phillippe
michelle_philippe@papajohns.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/986cf488-0e05-4a75-bc07-98ddf1c70095

More of what Papa Johns does best, now in a bigger size for just $19.99

EDMONTON, Alberta, Nov. 02, 2026 (GLOBE NEWSWIRE) — Bigger is officially better at Papa Johns Canada. Beginning today, the brand is introducing its new 16-inch XL Pizza, bringing more of the flavour Canadians love in a size that lives up to its name.

At a full 16 inches, the new XL Pizza delivers big on flavour and quality. Made with fresh, never-frozen original dough, real cheese made from mozzarella, and signature pizza sauce made from vine-ripened tomatoes, it’s everything customers crave about Papa Johns, just bigger.

“There’s a reason we’re calling it XL. At 16 inches, it’s a seriously big pizza,” said Scott Lewis, General Manager, International Markets – Canada, at Papa Johns. “We wanted to give Canadians more of what they already love, and that’s exactly what we’ve done. It’s a great addition to our menu, and we’re excited to give customers another reason to order.”

For a limited time, Canadians can enjoy a 16-inch XL one-topping pizza for just $19.99 at participating Papa Johns restaurants nationwide. The offer is available from November 2, 2026, through January 3, 2027.

Customers can order through the Papa Johns app or online at papajohns.ca.

ABOUT PAPA JOHNS

Papa John’s International, Inc. (Nasdaq: PZZA) opened its doors in 1984 with one goal in mind: BETTER INGREDIENTS. BETTER PIZZA.^® Papa Johns believes that using high-quality ingredients leads to superior quality pizzas. Its original dough is made of only six ingredients and is fresh, never frozen. Papa Johns tops its pizzas with real cheese made from mozzarella, pizza sauce made with vine-ripened tomatoes that go from vine to can in the same day and meat free of fillers. It was the first national pizza delivery chain to announce the removal of artificial flavours and synthetic colours from its entire food menu. Papa Johns is co-headquartered in Atlanta, Ga. and Louisville, Ky. and is the world’s third-largest pizza delivery company with approximately 6,000 restaurants in approximately 50 countries and territories. For more information about the Company or to order pizza online, visit www.papajohns.ca or download the Papa Johns mobile app for iOS or Android.

Media – Papa Johns – North America

Michelle Phillippe
michelle_philippe@papajohns.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/986cf488-0e05-4a75-bc07-98ddf1c70095

WINTER PARK, Fla., Nov. 02, 2026 (GLOBE NEWSWIRE) — Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a technology company building the future of the commodity markets through tokenization, today announced that it will release its financial results for the third quarter on Thursday, November 12, 2026, and host a corresponding earnings and corporate update presentation that same day at 4:30 p.m. ET.

Streamex Q3 2026 Results & Corporate Update Call Details

Management will host a conference call and webcast at 4:30 p.m. ET on Thursday, November 12, 2026, to discuss Q3 2026 financial results and provide a business update.

Dial-in: (800) 715-9871 (U.S. toll-free) or +1 (646) 307-1963 (international)
Conference ID: 4933172
Webcast: https://ir.streamex.com/financial-information/quarterly-results

A replay will be available on the Company’s Investor Relations website at ir.streamex.com shortly after the call.

Management will take questions live during the call. Investors and analysts are also encouraged to submit questions in advance to ir@streamex.com.

About Streamex Corp.

Streamex Corp. (NASDAQ: STEX) is a technology and infrastructure company focused on the tokenization and digitalization of commodity real-world assets. Streamex delivers institutional-grade solutions that bridge traditional finance and blockchain-enabled markets through secure, regulated, and yield-bearing financial instruments.

For more information, visit www.streamex.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Streamex’s business strategy, future growth, product development, and liquidity initiatives. These statements are based on current expectations and assumptions that are subject to risks and uncertainties, many of which are beyond Streamex’s control, and actual results may differ materially. Factors that could cause such differences include, among others, market conditions, regulatory developments, and macroeconomic factors affecting digital asset markets. A discussion of these and other factors, including risks and uncertainties with respect to Streamex, is set forth in Streamex’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as may be supplemented or updated by Streamex’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by Streamex from time to time. Streamex undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.

Contacts

Streamex Press & Investor Relations
Laura Kiernan
Head of Investor Relations, Streamex Corp.
IR@streamex.com | 1-914-598-7733

Henry McPhie
Chief Executive Officer, Streamex Corp.
www.streamex.com | X.com/streamex

WINTER PARK, Fla., Nov. 02, 2026 (GLOBE NEWSWIRE) — Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a technology company building the future of the commodity markets through tokenization, today announced that it will release its financial results for the third quarter on Thursday, November 12, 2026, and host a corresponding earnings and corporate update presentation that same day at 4:30 p.m. ET.

Streamex Q3 2026 Results & Corporate Update Call Details

Management will host a conference call and webcast at 4:30 p.m. ET on Thursday, November 12, 2026, to discuss Q3 2026 financial results and provide a business update.

Dial-in: (800) 715-9871 (U.S. toll-free) or +1 (646) 307-1963 (international)
Conference ID: 4933172
Webcast: https://ir.streamex.com/financial-information/quarterly-results

A replay will be available on the Company’s Investor Relations website at ir.streamex.com shortly after the call.

Management will take questions live during the call. Investors and analysts are also encouraged to submit questions in advance to ir@streamex.com.

About Streamex Corp.

Streamex Corp. (NASDAQ: STEX) is a technology and infrastructure company focused on the tokenization and digitalization of commodity real-world assets. Streamex delivers institutional-grade solutions that bridge traditional finance and blockchain-enabled markets through secure, regulated, and yield-bearing financial instruments.

For more information, visit www.streamex.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Streamex’s business strategy, future growth, product development, and liquidity initiatives. These statements are based on current expectations and assumptions that are subject to risks and uncertainties, many of which are beyond Streamex’s control, and actual results may differ materially. Factors that could cause such differences include, among others, market conditions, regulatory developments, and macroeconomic factors affecting digital asset markets. A discussion of these and other factors, including risks and uncertainties with respect to Streamex, is set forth in Streamex’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as may be supplemented or updated by Streamex’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by Streamex from time to time. Streamex undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.

Contacts

Streamex Press & Investor Relations
Laura Kiernan
Head of Investor Relations, Streamex Corp.
IR@streamex.com | 1-914-598-7733

Henry McPhie
Chief Executive Officer, Streamex Corp.
www.streamex.com | X.com/streamex